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Abstract Rapid technetium-99 m methoxyisobutyli-
sonitrile (99 mTc-MIBI) washout has been shown to
occur in impaired myocardia. This study is based on the
hypothesis that scintigraphy can be applied to calculate
the myocardial 99 mTc-MIBI washout rate (WR) to
diagnose and evaluate heart failure severity and other
left ventricular functional parameters specifically in
idiopathic dilated cardiomyopathy (IDCM) patients.
Patients with IDCMP (n = 17; 52.65 ± 11.47 years)
and normal subjects (n = 6; 49.67 ± 10.15 years) were
intravenously administered 99 mTc-hexakis-2-methox-
yisobutylisonitrile (99 mTc-MIBI). Next, early and
delayed planar data were acquired (at 3.5-h intervals),
and electrocardiogram (ECG)-gated myocardial perfu-
sion single photon emission computed tomography
(SPECT) was performed. The 99 mTc-MIBI WR was
calculated using early and delayed planar images.
Left ventricular functional parameters were also ana-
lyzed using quantitative gated SPECT (QGS) data. In
target group, myocardial WRs (29.13 ± 6.68%) were
significantly higher than those of control subjects
(14.17 ± 3.31%; P \ 0.001). The 99 mTc-MIBI
WR increased with the increasing severity of the
NYHA functional class (23.16 ± 1.72% for class I,
30.25 ± 0.95% for class II, 32.60 ± 6.73% for class III,
and 37.50 ± 7.77% for class IV; P = 0.02). The WR
was positively correlated with the end-diastolic volume
(EDV) index (r2 = 0.216; b = 0.464; P = 0.02
[ml/m2], the end-systolic volume (ESV) index (r2 =
0.234; b = 0.484; P = 0.01 [ml/m2]), the summed
motion score (SMS) (r2 = 0.544; b = 0.738;
P = 0.00), and the summed thickening score (STS)
(r2 = 0.656; b = 0.810; P = 0.00); it was negatively
correlated with the left ventricular ejection fraction
(LVEF) (r2 = 0.679; b = –0.824; P = 0.00). It can be
concluded that 99 mTc-MIBI scintigraphy might be a
valuable molecular imaging tool for the diagnosis and
evaluation of myocardial damage or dysfunction
severity.
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Introduction
Idiopathic dilated cardiomyopathy (IDCM) is a
primary myocardial disease of unknown cause char-
acterized by left ventricular or biventricular dilatation
and impaired myocardial contractility and it consist-
ing of 50% of total dilated cardiomyopathy [1–3] and
causes substantial morbidity and mortality, despite
major therapeutic achievements [3, 4]. The heart is
exclusively dependent on the mitochondrial respira-
tory chain for its energy demand and cardiomyopathy
has been observed as a common feature in patients
with mitochondrial diseases [5–8]. Myocardial met-
abolic failure (cytopathy) and ischemia caused by
arterial mitochondrial dysfunction (angiopathy) are
among possible pathogeneses for mitochondrial car-
diomyopathy [5].
The evaluation of respiratory chain failure is
clinically important in patients with mitochon-
drial cardiomyopathy; however, there is no useful
tool available for in vivo evaluation. Almost 90%
of technetium 99 m methoxyisobutyl isonitrile (99
mTc-MIBI) inside myocardial cells is contained
within the mitochondria [9] and is retained for a
relatively long time without any considerable change
in distribution [10]. Observation has suggested that
the clearance of 99 mTc-MIBI can be used to assess
ongoing myocardial damage in patients with conges-
tive heart failure (CHF) due to any cause [11, 12].
However, previous reports have mainly assessed the
99 mTc-MIBI washout rate (WR) in subjects with
heart failure resulting from known causes. In this
study, we aimed to evaluate whether the severity of
CHF resulting from IDCM can be evaluated using the
99 mTc-MIBI WR.
Materials and methods
Participants and study design
Seventeen patients in different stages of dilated
cardiomyopathy (DCM) (New York Heart Association
class I to IV and decreased left ventricular ejection
fraction (LVEF) (target) and six healthy control
subjects were studied. The DCM diagnosis was based
on increased left ventricular dimensions, a globally
decreased contraction pattern as determined by echo-
cardiography, and the absence of ischemic heart
disease (IHD) assessed by scintigraphy and/or angi-
ography. Patients were excluded if there was evidence
of prior myocardial infarction, underlying valvular
pathology according to echocardiography, uncon-
trolled systemic hypertension, or any other systemic
disease. Physical examination, electrocardiography,
echocardiography, and laboratory analysis confirmed
that the six healthy controls included in the study had
no history of ischemia or abnormality. All healthy
controls were in the low-risk category of pretest
likelihood of coronary artery disease (CAD) estimated
by means of nomograms [13].
The study complies with the Declaration of
Helsinki and was approved by the Institutional Ethics
Committee of Shaheed Beheshti University of Med-
ical Science in Tehran. All patients gave written
informed consent.
Study protocol
Gated 99 mTc-MIBI SPECT
Thirty minutes after administration of 740 MBq
99 mTc-MIBI and early planar imaging, gated single
photon emission computed tomography (SPECT) was
performed using a prefixed RR interval at a rate of
eight frames per cardiac cycle and a rotating, single
head gamma camera (Solus, ADAC, Milpitas, CA)
equipped with a low-energy, all purpose parallel-hole
collimator. A 20% window around the photo-peak
energy of 99 mTc-MIBI (140 keV) was used. Patients
were in a supine position during imaging. Thirty-two
projections (35 s/projection) were obtained in a 180-
degree circular orbit, beginning from 45 degrees right
anterior oblique to 135 degrees left posterior oblique
with step/shoot acquisition. A 64 9 64 9 16 matrix
was used. Cine-display images of the rotating planar
projections were reviewed on screen to assess the sub-
diaphragmatic activities, attenuations, and patient
motion. The LVEF (%), end-diastolic volume
(LVEDV, ml), and end-systolic volume (LVESV,
ml) were automatically calculated from the ECG-
gated SPECT data with 99 mTc-sestamibi using the
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quantitative gated SPECT (QGS) program (Cedars-
Sinai Medical Center) Table 1.
Parametric analysis
Thirty minutes and 3.5 h after 99 m Tc-MIBI injec-
tion, cardiac uptake was quantified in planar anterior
views in a 256 9 256 matrix for 5 min. As shown in
Fig. 1, the regions of interest on the planar images
were the mediastinum and the heart in order to
quantify cardiac 99 m Tc-MIBI uptake in terms of
the heart-mediastinum (H/M) count ratio in the early
(e) and delayed (d) views. The mean count per pixel
was considered. The 99 m Tc-MIBI WR (%) was
calculated based on the Flotats et al. formula [14]:
H
M
; WR ¼ He  ðHd=DFÞ
He
 100
He Heart early count; M Upper mediastinum count;
Df Decay factor time; Hd Cardiac delayed count.
In addition, the raw EDV and ESV data were
divided by body surface area (BSA), and the end-
diastolic volume (EDV) index and the end-systolic
volume (ESV) index were acquired. The BSA was
calculated using the following formula [15]:
Body Surface area ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
weightðkgÞ  heightðcmÞ
3600
r
EDVI (ml/m2) = EDV/BSA
ESVI (ml/m2) = ESV/BSA
Statistical analysis
The data were expressed as mean ± SD, Man–
Whitney U test and Kruskal–Wallis test were used
for quantitative comparison, and differences in pro-
portion (categorical variables) were examined using
chi-square test. Linear regression was used to analyze
the relationship between the WR and the gated
SPECT findings. A P value of \ 0.05 was considered
statistically significant. Statistical analysis was per-
formed using an IBM computer and PASW software,
version 18.0 (SPSS, Inc., Chicago, USA).
Results
Twenty-three patients, 17 with IDC (CHF group; 9
men and 8 women; mean age of 52.65 ± 11.47 years;
New York Heart Association [NYHA] functional class
I to IV) (target) and six normal controls (NC group; 1
man and 5 women; mean age of 49.67 ± 10.15 years)
were included in this study.
According to the echocardiography results, the
ejection fraction (EF) of the patients was 28.82 ±
11.39% and it was 65.50 ± 5.26% for the control
group (P = 0.00). The LVEDV and LVESV indices
were significantly greater and LVEF was lower
in patients with CHF than in healthy volunteers
(Table 2). The 99 mTc-MIBI WR was significantly
higher in target (29.13 ± 6.68%) than in the control
group (14.17 ± 3.31%) (P = 0.001), whereas H/M
ratios according to early and delayed images did not
Table 1 The basic data in two target and control groups
Target Control P value
Age (year) 52.65 ± 11.47 49.67 ± 10.15 0.609
Sex (M/F) 9/8 1/5 0.12
BMI (kg/m2) 25.07 ± 4.1 25.03 ± 2.09 0.973
SBP (mm Hg 122.06 ± 19.93 115.83 ± 4.45 0.708
HR (beat/min) 81.59 ± 13.87 73.83 ± 4.45 0.052
LVEF (%) 28.82 ± 11.39 65.50 ± 5.26 0.00
NYHA (I/II/III/IV) 6/4/5/2 NA NA
BMI Body mass index; SBP Systolic blood pressure; HR Heart
rate; LVEF Left ventricle ejection fraction according to
echocardiography; NYHA New York heart association; NA
Not applicable
Fig. 1 Calculation of myocardial washout rate using planar
99mTc-MIBI imaging
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differ in either group (P values of 0.286 and 0.658,
respectively).
The WR was positively correlated with the end-
diastolic volume (EDV) index (r2 = 0.216;
b = 0.464; P = 0.02 [ml/m2], the end-systolic vol-
ume (ESV) index (r2 = 0.234; b = 0.484; P = 0.01
[ml/m2]), the summed motion score (SMS)
(r2 = 0.544; b = 0.738; P = 0.00), and the summed
thickening score (STS) (r2 = 0.656;b = 0.810;
P = 0.00); it was negatively correlated with the left
ventricular ejection fraction (LVEF) (r2 = 0.679;
b = -0.824; P = 0.00). The association between
cardiac function parameters using gated SPECT and
WRs is shown in Figs. 2, 3, 4, 5, 6. The mean WR
across four classes was compared using Kruskal–
Wallis test; it was 23.16 ± 1.72% for class I;
30.25 ± 0.95% for class II; 32.60 ± 6.73% for class
III, and 37.50 ± 7.77% for class IV, which had
significant differences (P value = 0.02) [Fig. 7].
Discussion
Myocardial uptake and retention of 99 m Tc-MIBI
involve passive diffusion across the plasma and
mitochondrial membranes [9]. Mitochondrial mem-
brane integrity is required for the intracellular binding
of 99 m Tc-MIBI, and mitochondrial injury results in
extracellular leakage of the tracer [5, 16, 17].
Beanlands et al. showed that irreversible cellular
injury caused by cytochrome c oxidase inhibitor
sodium cyanide and sarcolemmal membrane detergent
Triton X-100 resulted in an increase in the 99 mTc-
sestamibi clearance [10]. Markers of oxidative stress
are shown to increase in CHF patients and have been
correlated with myocardial dysfunction and overall
severity of heart failure [4]. In mitochondrial respira-
tory chain failure, energy production shifts from the
aerobic to the glycolytic pathway result in augmented
lactic acid production and increased uptake of 123I-
beta-methyl-iodophenyl pentadecanoic acid (BMIPP)
[5]. Thus, the 99 mTc-MIBI/123I-BMIPP mismatch,
together with the increased 99 mTc-MIBI WR,
appears to be a sign of mitochondrial respiratory
Table 2 The scintigraphic findings in two target and control
groups
Target Control P value
H/M (e) 2.72 ± 0.4 2.47 ± 0.14 0.286
H/M (d) 3.00 ± 0.38 3.04 ± 0.31 0.658
WR (%) 29.13 ± 6.68 14.17 ± 3.31 0.001
LVEF (%) 28.12 ± 11.96 71.17 ± 4.36 0.001
EDVI (ml/m2) 111.82 ± 69.5 40.50 ± 6.05 0.000
ESVI (ml/m2) 86.00 ± 68.98 12.00 ± 2.89 0.000
SV (ml) 44.35 ± 10.97 49.17 ± 3.31 0.074
SMS 40.94 ± 19.28 0.5 ± 0.84 0.001
STS 29.35 ± 11.54 0.33 ± 0.52 0.001
H/M(e) Heart/mediastinum count ratio in early image; H/M(d)
Heart/mediastinum count ratio in delay image; WR Washout
rate; LVEF (%) Left ejection fraction according to gated
myocardial perfusion imaging; EDVI End-diastolic volume
index; ESVI End-systolic volume index; SV Stroke volume;
SMS Sum motion score; STS Sum thickening score
Fig. 2 The association between the 99mTc-MIBI washout rate
and ejection fraction using gated SPECT
Fig. 3 The association between the 99mTc-MIBI washout rate
and end-systolic volume index (ESVI) parameters using gated
SPECT
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failure and may reflect the severity of cardiac
involvement.
The 99 mTc-MIBI WR increased in target and
reached the maximum in class IV patients who
showed severe cardiac failure reflecting respiratory
chain failure (Table 2). This is in accordance with
previous reports [16, 18, 19]. In this study, although
differences in the early and delayed H/M ratio were
not statistically significant between the two groups,
the myocardial 99 mTc-sestamibi WR in the target
group (29.13 ± 6.68%) were significantly higher
than those in the control group (P B 0.01). This is
consistent with a previous report stating that the
initial 99 m Tc-MIBI uptake rate (at 40–60 min) was
higher in cultured chick embryo cardiac myocytes
with mild to moderate metabolic injury than in those
without such injury [20].
In addition, the myocardial WRs of all subjects
correlated well with left ventricular function in the
current investigation. Insufficient adenosine triphos-
phate (ATP) production caused by mitochondrial
dysfunction in damaged myocardia may be related to
concordant findings of 99 mTc-sestamibi rapid wash-
out and left ventricular dysfunction [5].
In a study by Kumit et al., the myocardial WRs for
25 CHF patients were significantly higher than for
Fig. 4 The association between the 99mTc-MIBI washout rate
and end-diastolic volume index (EDVI) parameters using gated
SPECT
Fig. 5 The association between the 99mTc-MIBI washout rate
and sum motion score (SMS) parameters using gated SPECT
Fig. 6 The association between the 99mTc-MIBI washout rate
and sum thickening score (STS) parameters using gated
SPECT
Fig. 7 The mean 99mTc-MIBI washout rate in patients with
different functional classes according to New York Heart
Association [NYHA] classification
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those in the control group (39.6 ? 5.2% vs.
31.2 ? 5.5%; P \ 0.01) and they correlated with
functional cardiac parameters. Myocardial WRs did
not demonstrate a statistically significant difference
between patients with and without hypoperfused
areas on myocardial perfusion SPECT, and it is
suggested that washout of the hypoperfused areas did
not necessarily contribute to the rapid washout in the
CHF group [18]. In another study by Sugiura et al.,
the 99 mTc-MIBI WR was higher in CHF patients
(31.2% ± 6.3%) than in healthy controls (25.2% ±
4.7%; P \ 0.05). There were positive correlations
between the 99 mTc-MIBI WR and brain natriuretic
peptide levels (r = 0.723; P \ 0.0001) and a nega-
tive correlation between the 99 m Tc-MIBI WR and
the LVEF (r = -0.545; P \ 0.01). The 99 mTc-
MIBI WR correlated with that of metaiodobenzyl-
guanidine(MIBG) (r = 0.603; P \ 0.01). They also
demonstrated that 99 mTc-MIBI scintigraphy is use-
ful in evaluating the severity of CHF [16].
Recently, Matsuo and et al. showed that the
myocardial 99 mTc-MIBI WR is a novel marker for
the diagnosis of myocardial damage or dysfunction,
providing prognostic information for patients with
CHF [19].
There were good correlation between the WR of
99 mTc-MIBI and the LVEF on 99 mTc-MIBI gated
SPECT, possibly due to impaired mitochondria in the
myocardium that accumulated in the heart wall to
compensate for the energy decline due to respiratory
chain failure [5]. P-glycoprotein (P-gp) might also
influence the uptake and WR of 99 mTc-MIBI [21].
In addition, several studies revealed a variable
degree of interstitial and perivascular fibrosis in
IDCMP that leads to decreased myocardial tissue
perfusion in this subgroup as fibrotic tissue is unable to
rapidly exchange water across the barriers. This also
might explain the higher WR in this subgroup [2].
Patients with ischemic heart failure (IHF) have a
worse prognosis [22], but may benefit from revascu-
larization, lipid-lowering drugs, and neurohormonal
blockades [23, 24]. Conversely, in patients with IDCM,
genetic screening of family and exclusion of IHD by
noninvasive methods are becoming more important in
diagnosing and managing the disease [25]. Assessment
of myocardial perfusion and regional ventricular
function using exercise technetium-99 m sestamibi
gated SPECT imaging can reliably distinguish between
patients with ischemic cardiomyopathy and patients
with nonischemic dilated cardiomyopathy [26, 27].
Likewise, addition of the WR value to usual SPECT
data may help to determine prognosis with more
accuracy.
It may be helpful to compare the myocardial WRs
with several biomarkers, such as TNF and O2
-, and
to prove myocardial damage in the CHF group and
the correlation with scintigraphic findings. Follow-up
studies are also required to clarify the relationship
between the 99 mTc-sestamibi myocardial washout
and patient outcome, including left ventricular func-
tional outcome and prognosis for CHF patients.
This study had a few limitations. We did not test
the role of permeability glycoprotein (P-gp) in
99 mTc-MIBI washout. Overexpression of P-gp
would enhance WRs. This hypothesis could be tested
by enrollment of patients with CHF after treatment
with specific P-gp inhibitors. In addition, the calcu-
lation of WRs at different times following 99
mTc-MIBI administration (earlier than 3.5 h) is rec-
ommended in order to implementation of a study
during the shorter time.
Conclusion
The study demonstrated that the 99 mTc-MIBI WR
correlated with functional cardiac parameters using
myocardial perfusion imaging (MPI) in patients with
idiopathic dilated cardiomyopathy. As a result,
99 mTc-MIBI scintigraphy might be a valuable
molecular imaging tool for the diagnosis and evalu-
ation of myocardial damage or dysfunction severity.
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